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A B S T R A C T
Background
The long-term risk of stroke increases with age, and stroke is a common cause of disability in the community. Spasticity is considered
a significantly disabling impairment that develops in people who have had a stroke. The burden of care is higher in stroke survivors
who have spasticity when compared with stroke survivors without spasticity with regard to treatment costs, quality of life, and caregiver
burden.
Objectives
To assess if pharmacological interventions for spasticity are more effective than no intervention, normal practice, or control at improving
function following stroke.
Search methods
We searched the Cochrane Stroke Group Trials Register (May 2016), the Cochrane Central Register of Controlled Trials (CENTRAL,
2016, Issue 5), MEDLINE (1946 to May 2016), Embase (2008 to May 2016), CINAHL (1982 to May 2016), AMED (1985 to May
2016), and eight further databases and trial registers. In an effort to identify further studies, we undertook handsearches of reference
lists and contacted study authors and commercial companies.
Selection criteria
We included randomised controlled trials (RCTs) that compared any systemically acting or locally acting drug versus placebo, control,
or comparative drug with the aim of treating spasticity.
Data collection and analysis
Two review authors independently assessed the studies for inclusion and extracted the data. We assessed the included studies for both
quality and risk of bias. We contacted study authors to request further information when necessary.
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Main results
We included seven RCTs with a total 403 participants. We found a high risk of bias in all but one RCT. Two of the seven RCTs assessed
a systemic drug versus placebo. We pooled data on an indirect measure of spasticity (160 participants) from these two studies but found
no significant effect (odds ratio (OR) 1.66, 95% confidence interval (CI) 0.21 to 13.07; I2 = 85%). We identified a significant risk of
adverse events per participant occurring in the treatment group versus placebo group (risk ratio (RR) 1.65, 95% CI 1.12 to 2.42; 160
participants; I2 = 0%). Only one of these studies used a functional outcome measure, and we found no significant difference between
groups.
Of the other five studies, two assessed a systemic drug versus another systemic drug, one assessed a systemic drug versus local drug, and
the final two assessed a local drug versus another local drug.
Authors’ conclusions
The lack of high-quality RCTs limited our ability to make specific conclusions. Evidence is insufficient to determine if systemic
antispasmodics are effective at improving function following stroke.
P L A I N L A N G U A G E S U M M A R Y
Drugs (with the exception of botulinum toxin) to treat spasticity after stroke
Question
Are drugs (with the exception of botulinum toxin) better than a placebo or control in treating spasticity in people with stroke?
Background
We wanted to learn whether there was evidence for using drugs for spasticity in people with stroke, and if so, to identify whether drugs
that acted on the whole body (systemic drugs) differed in their effects to drugs that acted in a localised area of the body (local drugs).
Study characteristics
We included seven studies involving a total of 403 participants. The evidence is current to May 2016. There were variations among the
included studies. Two of the studies were placebo controlled, while the rest compared one drug to another drug. Two studies compared
two systemic drugs against each other; two studies compared two local drugs against each other; and the fifth study compared a systemic
drug against a local drug.
Key results
The results for the studies varied, meaning that we could make no clear conclusions. The two studies that used a placebo as a control
provided conflicting results; when the results were combined we identified a slight benefit in favour of the treatment group. These two
studies provided clear evidence that taking the treatment drug was likely to result in an increased risk of having an adverse event. This
review identified a lack of studies and subsequent evidence relating to the use of pharmacological interventions (with the exception of
botulinum toxin) to treat spasticity. Future research to identify the best time to start treatment and the optimal dose for treatment is
recommended.
Quality of the evidence
The quality of the evidence varied.We judged all but one of the studies to be at high risk of bias in at least one of the six areas considered.
The sample sizes in the included studies were relatively low for drug trials; three of the seven studies had 30 or fewer participants.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Systemic antispasticity drugs compared with placebo for spasticity after stroke
Patient or population: people with spast icity following stroke
Settings: community
Intervention: systemic ant ispast icity drugs
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Systemic antispastic-
ity drugs
Indirect measure of
spasticity
Modif ied Ashworth
Scale
Follow-up: 4 or 6 weeks
Study population OR 1.66
(0.12 to 15.38)
160
(2 studies)
⊕©©©
very low1,2,3,4
-
49 per 100 57 per 100
(10 to 94)
Low
- -
Adverse events
Adverse events per par-
t icipant
Follow-up: 4 or 6 weeks
Study population RR 1.65
(1.12 to 2.42)
160
(2 studies)
⊕©©©
very low1,3
-
40 per 100 65 per 100
(44 to 96)
Low
- -
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; OR: odds rat io; RR: risk rat io
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Unclear how random sequence generat ion was carried out in either study.
2Results very heterogenous (I2 = 90%).
3The studies did not invest igate the same drug against a placebo.
4Both studies appeared to select ively report results. The corresponding author of the Stamenova 2005 study was an employee
of the company that manufactured the drug.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
The long-term risk of stroke increases with age. The risk of stroke
over an expected lifetime has been calculated at between 1 in 5
for females and 1 in 6 for males in a group of middle-aged adults
(Seshadri 2006). A stroke will have a greater impact on a person
than any other chronic disease (Adamson 2004). Stroke causes a
range of disabilities, one ofwhich is spasticity. The burdenof care is
higher in stroke patients who have spasticity when compared with
stroke patients without spasticity with regard to treatment costs,
quality of life, caregiver burden, and the effects of comorbidities
(Esquenazi 2011).
Description of the condition
Spasticity occurs as a result of damage to the descending tracts of
the upper motor neuron system. This generally involves damage
to the corticoreticular pathways (para-pyramidal pathways), tracts
originating at the brain stem or reticular formation (e.g. the retic-
ulospinal and vestibulospinal tracts) (Burke 1988). Such damage
to the upper motor neuron system results in a loss of descending
control that in turn manifests as abnormal muscle activity to an
externally imposed stimuli.
Spasticity is poorly defined in the literature (Malhotra 2009). For
the purposes of this review, in order to ensure that no data were
missed,we defined spasticity as “disordered sensory-motor control,
resulting from an upper motor neuron lesion, presenting as inter-
mittent or sustained involuntary activation of muscles” (Pandyan
2005).
Spasticity is common, with prevalence ranging from 30% to 80%
of stroke survivors (Malhotra 2008;Watkins 2002). Spasticity that
is not treated effectively can result in increased pain and stiffness,
decreased range of movement, and altered posturing (Ada 2006;
Malhotra 2008). It may also interfere with functional recovery
(Sorinola 2009). However, the complexity of differentiating be-
tween neural and intrinsic stiffness makes the correlation between
function and spasticity difficult to identify (Mirbagheri 2011). In
spite of this, many studies have used a functional measure to pri-
marily assess the efficacy of the intervention. As the aim of re-
habilitation is to facilitate and optimise the recovery of function,
this review focused primarily on whether current treatments of
spasticity lead to improvements in function, despite there being
a lack of evidence of a causal relationship between spasticity and
function.
Description of the intervention
The treatment of spasticity can be complex and relies on a multi-
disciplinary approach (Barnes 1998). Treatment of spasticity has
traditionally taken a stepped approach whereby conservative pro-
cedures are used first and progressively more invasive procedures
are then employed (Bogey 2004; Rekand 2010). Physiotherapeu-
tic approaches are deemed the most conservative and are therefore
used initially. This is reinforced by consensus guidelines (Royal
College of Physicians 2009; Sheean 2010). However, physiothera-
peutic interventions do not have a direct effect on abnormal mus-
cle activity (there are some unproven claims that there may be an
indirect effect) resulting from spasticity; this can only be achieved
by pharmacological interventions.
Pharmacological interventions for stroke spasticity are generally
termed antispasmodics and can be divided into two groups: those
that act systemically and those that act locally (Sheean 2006),
with the locally acting treatments tending to be more invasive.
The stepped approach advocates that systemically acting drugs
be used initially (Gormley 1997). Such drugs include baclofen,
tizanidine, or dantrolene. If these are not successful in alleviating
the problem, then locally acting drugs are employed (Bogey 2004),
such as injections of botulinum toxin to the muscles or alcohol or
phenol to the peripheral nerves (Kocabas 2010). Should none of
these treatments be effective, then surgery is the final treatment
option. However, this is rarely used in the stroke population.
The use of physical therapeutic methods to manage spasticity is
currently being systematically reviewed (Monaghan 2011), as is
the use of botulinum toxin, which is the most widely used locally
acting pharmacological therapy (Lyons 2007). However, the use
of systemically acting drugs and other locally acting drugs has not
been systematically reviewed. This review therefore focused on
these systemically and locally acting drugs, excluding those tech-
nologies already under review (i.e. botulinum toxin and physio-
therapeutic interventions).
How the intervention might work
Drugs act either systemically or peripherally. Systemic drugs act
in a number of different ways but generally aim to inhibit neuro-
transmitter activity at one or more sites within the central nervous
system. Sites of action include both pre- and post-synaptic termi-
nals of the spinal interneurons (at varying levels of the upper mo-
tor neuron pathway), alpha motor neurons, and primary sensory
afferent neurons. This inhibitory effect acts on the neurotrans-
mitters throughout the central nervous system and can result in
drowsiness amongst other side effects (Gracies 1997). Administra-
tion tends to be oral, so doses need to be high for the active agent
in the drug to cross the blood-brain barrier. In order to lessen these
negative effects it is possible to introduce some drugs directly into
the cerebrospinal fluid via an intrathecal pump. One particular
group of drugs inhibits force production at the level of themuscle;
however, this effect can also be systemic.
Other drugs are given peripherally via injection directly to the
nerve. This is a far more invasive procedure; however, the systemic
side effects are fewer. The aim of such injections is to destroy
conduction in the nerves or the release of transmitters at themotor
neuron junction or to decrease muscle contraction.
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We have provided an outline of the most regularly used drugs.
While not systemically acting, we have also included alcohol and
phenol in Table 1.
Why it is important to do this review
Using antispasmodics that have systemic effects appears to remain
pervasive in the clinical setting. There is evidence that global an-
tispasmodics tend to depress the nervous system (Gracies 1997;
Simpson 2009). This in turn can be detrimental to motor skill
acquisition (Sheean 2009; Willerslev-Olsen 2011). As these phar-
macological therapies are started during rehabilitation, where the
main objective is to relearn motor skills, such drugs may not be
appropriate. There was therefore a need to review the level of evi-
dence on which these drugs are used.
Phenol and alcohol are locally acting drug treatments, but their
effectiveness has not been systematically reviewed with regard to
poststroke spasticity, and so we have included these in our review.
The management of spasticity poststroke using physical therapeu-
tic means is being systematically reviewed, having been accepted
as a protocol (Monaghan 2011), and a systematic review of bo-
tulinum toxin poststroke is currently being reviewed by editors
(Lyons 2007); we therefore have not included these in this review.
It is unclear whether one drug is more effective than another in
treating both spasticity and the prevention of secondary conse-
quences, and whether any effects translate into functional im-
provements.
It is also important to assess what common adverse events are
identified with the use of such drugs.
O B J E C T I V E S
To assess if pharmacological interventions for spasticity are more
effective than no intervention, normal practice, or control at im-
proving function following stroke.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials in this review. Studies
had to have investigated any pharmacological therapy; this was
not limited to the drugs documented in Table 1. Systemically act-
ing drugs tend to have a long half-life and will therefore carry a
high risk of carry-over effect. We planned to include studies with
a cross-over design if the results of the first period of the data (i.e.
before cross-over) were available. We contacted the study authors
to request this information if it was not included in the published
article. Some studies combined complex combinations of phar-
macological interventions with physical therapeutic interventions
where there was no clear placebo or normal treatment group. We
identified in the protocol that we would not include such studies,
as it would be difficult to ascertain what part of the treatment
provided the main effect.
Types of participants
We included participants who have had a stroke resulting in spas-
ticity. There is evidence that spasticity is poorly defined and mea-
sured in the literature (Malhotra 2009). Excluding papers using
invalid outcome measures was likely to result in very few papers
left to review. We therefore included all trials that explicitly stated
that the aim was to treat spasticity (it was possible to ascertain that
this was the case by reading the appropriately selected papers). A
variety of methods are available to measure aspects of spasticity,
some that are direct (neurophysiological methods such as Hoff-
mann reflex (H-reflex) and electromyography) and others that are
not (biomechanical measures such as stiffness or clinical scales
such as the Ashworth Scale or Tone Assessment Scale).Most of the
commonly used measures are indirect and confounded (Fleuren
2010). We excluded studies where no outcome measure of spas-
ticity had been used.
We included participants irrespective of gender and older than
18 years of age. Some studies included participants with a variety
of diagnoses (e.g. traumatic brain injuries or multiple sclerosis
as well as stroke). In such cases we contacted the study authors
to request stroke-specific data. If study authors were not able to
provide stroke-specific data, we still included the studies if the
proportion of participants with stroke was greater than 80%. We
did not include studies where the proportion of participants with
stroke was less than 80%.
Types of interventions
We included any pharmacological intervention that aimed to re-
duce spasticity regardless of dose or mode of delivery.
We included any pharmacological intervention that was com-
pared with a placebo, normal practice, or no intervention. We also
planned to include trials that compared two forms of antispasticity
intervention, as long as at least one intervention was pharmaco-
logical; however, we did not identify any such trials.
Types of outcome measures
There are wide variations in the types of outcome measures used
to assess the efficacy of antispasticity treatments. Many studies
use a variety of scales that attempt to assess disability at the level
of impairment, activity, and participation. As elucidated already,
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the main aim of rehabilitation is to achieve functionally relevant
activity that transfers into usual activities of daily living. Such
scales tend to be general and not dependent on specific areas of
the body. However, other activity scales are more localised. We
decided that such specific outcome measures should be divided
into those assessing upper limb and those assessing the lower limb.
Primary outcomes
1. Functional ability during activities of daily living.
Secondary outcomes
We identified functional movement scales that measure activity
at the upper limb separately to those that measure activity at the
lower limb with a view to analysing them separately; however, this
was not possible due to the methods used in the included studies.
1. Secondary consequences of spasticity, assessed by specific
objective measures such as pain and range of movement.
2. Spasticity, either measured through neurophysiological
methods, such as electromyographic (EMG) activity or H-reflex
activity, or using indirect measures of stiffness such as the
Modified Ashworth Scale or Tone Assessment Scale. While the
Modified Ashworth Scale and Tone Assessment Scale are not
necessarily measures of spasticity, such measures are commonly
used so we also included them.
3. Adverse events.
Search methods for identification of studies
See the ’Specialized register’ section in the Cochrane Stroke Group
module. We searched for trials in any language and attempted to
arrange translation of relevant papers published in languages other
than English.
Electronic searches
We searched the Cochrane Stroke Group Trials Register (last
searched 19May 2016) and the following electronic bibliographic
databases and trials registers:
• The Cochrane Central Register of Controlled Trials
(CENTRAL 2016, Issue 5) (Appendix 1);
• MEDLINE (Ovid) (1946 to 17 May 2016) (Appendix 2);
• Embase (Ovid) (2008 to 17 May 2016) (Appendix 3);
• CINAHL (EBSCO) (1982 to 17 May 2016) (Appendix 4);
• AMED (Ovid) (1985 to 17 May 2016) (Appendix 5);
• Physiotherapy Evidence Database (PEDro) (
www.pedro.org.au/) (13 May 2016);
• REHABDATA (www.naric.com/?q=en/REHABDATA)
(13 May 2016);
• Center for International Rehabilitation Research
Information and Exchange (CIRRIE) (cirrie.buffalo.edu/) (13
May 2016);
• ClinicalTrials.gov (www.clinicaltrials.gov/) (13 May 2016);
• EU Clinical Trials Register (www.clinicaltrialsregister.eu)
(13 May 2016);
• Stroke Trials Registry (www.strokecenter.org/trials/) (13
May 2016);
• ISRCTN Registry (www.isrctn.com/) (previously Current
Controlled Trials: www.controlled-trials.com) (13 May 2016);
• World Health Organization International Clinical Trials
Registry Platform (apps.who.int/trialsearch/) (13 May 2016).
We developed the MEDLINE search strategy with the help of the
Cochrane Stroke Group Information Specialist and adapted it for
the other databases.
Using a comprehensive search strategy, theCochrane StrokeGroup
Information Specialist has already completed a retrospective search
of Embase for all stroke trials to January 2008 and added all rele-
vant trials to the Cochrane Stroke Group Trials Register. In order
to avoid duplication of efforts, we have limited the search of this
database from January 2008 onwards.
Searching other resources
In order to identify further published, unpublished, and ongoing
trials, we:
• searched the reference lists of published reviews and trials
identified by the above methods;
• contacted the following pharmaceutical companies:
Novartis (baclofen) April 2014; Strathmann (tolperisone) April
2014; Sanochemia (tolperisone) April 2014; Acorda (tizanidine)
April 2014;
• contacted authors and researchers in the field;
• used Science Citation Index Cited Reference Search for
forward tracking of important articles.
Data collection and analysis
Two review authors (CL and AK) independently screened the ti-
tles and abstracts of all the records obtained from the electronic
searches and excluded obviously irrelevant studies. We then ob-
tained the full text of the remaining studies, and the same two
review authors independently selected studies that met the review
inclusion criteria (types of studies, types of participants, aims of
interventions, and outcome measures).
Selection of studies
Two review authors (CL and AK) independently considered all
intervention studies and identified those that were randomised
controlled trials. If there was disagreement between review authors
following the independent review process, we reached consensus
through discussion.
As recommended in the PRISMA statement (Moher 2009), we
have included a flow diagram outlining the phases for selection
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of studies included in the review using the PRISMA template
available in Review Manager 5 (RevMan 2014).
Data extraction and management
Having identified all randomised controlled trials, two review au-
thors (CL and CS) independently assessed each study and ex-
tracted the relevant details using a data extraction form (Appendix
6) based on a modified version of the van Tulder pro-forma previ-
ously advocated for assessment of risk of bias by theCochrane Back
Review Group (van Tulder 1997). This pro-forma is designed to
assess risk of bias, but also contains items that relate to quality and
precision of reporting rather than internal validity.
Assessment of risk of bias in included studies
Two review authors (CL and CS) independently assessed each
study for risk of bias using Cochrane’s tool for assessing risk of bias
in included studies (Higgins 2011). In cases where there was not
enough information to make a clear decision, we contacted the
study authors and requested clarification or further information.
We then made a decision on whether there was a low risk, high
risk, or unclear risk of bias for all included studies in each of the
five domains of the Cochrane ’Risk of bias’ tool (Higgins 2011).
These domains are presented as five questions.
Was random sequence generation adequate?
We deemed studies to have a low risk of bias if the study described
an adequate random component in the sequence generation pro-
cess. Methods might have included computer-generated random
number, coin tossing, throwing dice, or drawing lots. We consid-
ered studies to be at high risk of bias if a non-random method
for sequence generation was described. Such methods might have
included birthdays, hospital numbers, or non-random categorisa-
tion. In studies where there was not enough information to make
a judgement of ’low risk’ or ’high risk’, we classified the study as
’unclear’.
Was allocation adequately concealed?
If a centralised randomisation, computerised allocation, or the
picking of opaque envelopes (which all required participant details
to be provided prior to allocation) was used, then we considered
concealment to be adequate. We decided to deem a study to have
inadequate concealment if it includedusing anopen list containing
random numbers or contained on an open computer system. If
there was no or inadequate information described in the report,
then we classified the study as ’unclear’.
Was the allocated intervention adequately concealed
from the outcome assessor?
In studies where the outcome assessor was masked or blinded and
the report did not identify any unmasking, we deemed the study to
have adequate concealment. Inadequately concealed studies might
have described an unblinded assessor or assessor who became un-
blinded. In studies where no description of the assessors masked
status was described, we considered the study to be ’unclear’.
Were incomplete outcome data adequately
addressed?
We considered studies that reported all outcome data to have a
low risk of attrition bias. In cases where there was missing data,
but we deemed this data to be balanced across groups or unlikely
to relate to the outcome, we considered the study to be at low risk
of attrition bias. We deemed studies that inadequately addressed
missing outcome data as at high risk of attrition bias. In studies
where there was insufficient information to make a judgement, we
deemed attrition bias to be ’unclear’.
Were any other issues identified that increased the
high risk of bias?
We added any additional potential sources of bias identified during
the review in this section. Only those studies that were identified
as having a high risk of bias were marked. If there was no clear
indication of a high risk of bias, then we left the field blank. This
was because a lack of reporting made it difficult to distinguish
between a study that was unclear or had a low risk of bias.
Measures of treatment effect
By entering details from each study into Review Manager 5
(RevMan 2014), we were able to statistically analyse the treatment
effect. The outcomes studied used a variety of data. We analysed
dichotomous data as odds ratios (ORs) with 95% confidence in-
tervals (CIs). We presented pain and the presence of side effects as
dichotomous data. We also re-coded measures of stiffness such as
the Ashworth Scale into dichotomous data, identifying if there was
an improvement or not. This was necessary because (as expected)
there were many variations on the scale system, and it was not pos-
sible to compare such poorly defined ordinal scales as continuous
data. There is also no clinically significant cutoff point available
to use for these scales.
We analysed continuous data in two ways, depending on the mea-
sures used in studies. Examples of continuous data that we anal-
ysed in this way were the H-reflex or Barthel Index.
For separate studies where the same measure was used, we used
the mean difference (MD) with 95% CI to calculate treatment
effect. We intended to use standardised mean difference (SMD)
with 95% CI in cases where separate studies used different scales
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to measure the same outcome; however, this was not necessary due
to the lack of studies.
As some participants could have had more than one adverse event
and some participants may have had none, we analysed adverse
events as risk ratio (RR) with 95% CI.
Where an important outcome could not be summarised in the
way described above, we tabulated the results.
Unit of analysis issues
Due to the high risk of a carry-over effect in cross-over trials of
systemic medications, we planned to include only studies where
the the first-period data were available (i.e. a baseline measure and
then a further measure just before cross-over). We contacted the
study authors to request these data if they were not available in
the published article.
Dealing with missing data
In the case of missing data we contacted the original investigators
to request the information. As planned, it was possible to calculate
some missing data using calculations of provided data (as might
be the case in missing standard deviations). Where a study did
not report a designated outcome, we excluded the study from the
analyses of the outcome.
Assessment of heterogeneity
We expected that the studies would be clinically heterogeneous,
with variation in interventions and outcomes observed. In all in-
stances we could observe such variation visually using the forest
plot. We also used statistical methods to assess heterogeneity. We
deemed a Chi2 test with an χ2 greater than the number of studies
included minus 1 as significant heterogeneity.
We were also able to quantify the inconsistency and impact on the
meta-analysis using the I2 statistic (Higgins 2002). In this meta-
analysis we set an I2 statistic of up to 40% as an acceptable level
of heterogeneity.
Assessment of reporting biases
By using the search strategy outlined above to include and analyse
all positive or negative available data in any language, reporting bias
was kept to a minimum. We planned to subject any unpublished
trials to a detailed review prior to inclusion.
Data synthesis
The aim of this review was to establish whether there is evidence
of an effect. This type of review makes conducting a meta-analysis
appropriate. We expected that this review would identify studies
that used a variety of drugs to achieve the same outcome, though
measured in various ways. Should the pooled data from these stud-
ies demonstrate statistical homogeneity, then we intended to use
a fixed-effect meta-analysis. We considered it more likely that we
would need to use a random-effects model. We planned to report
themost conservative outcome in cases where there was divergence
(Deeks 2011).
In order to investigate the primary objective, we pooled studies
using continuous data. As described in the Measures of treatment
effect section, for separate studies where the same measure was
used, we used MD with 95% CI to calculate treatment effect;
for separate studies that used different scales to measure the same
outcome, we planned to employ SMD with 95% CI.
We intended to pool the timed functional tests using SMD with
95% CI.
In order to investigate the secondary outcomes of spasticity (and
pain and secondary consequences of spasticity), we pooled studies
using dichotomous outcomemeasures.We calculated anORusing
the Mantel-Haenszel statistical method with 95% CI to assess
treatment effect.
We intended to pool studies that used EMG or H-reflex to assess
spasticity and use MD with 95% CI to calculate treatment effect.
In order to determine if global antispasmodic interventions are
more effective than local treatments at improving function after
stroke, we intended to pool studies using the same drug to study
the effect of particular drugs. We intended to then pool the results
of locally or globally acting drugs.
In order to determine the rate of side effects, we planned to pool
the RRs of each trial using theMantel-Haenszel methodwith 95%
CI.
GRADE and ’Summary of findings’ table
We used the GRADE approach to assess the quality of the evi-
dence in the included studies. This system required two review
authors (CL and AK) to assess the quality of the evidence for each
individual outcome and rate it on a four-point scale from high
to very low. Randomised controlled trials began as high evidence
and were sequentially downgraded from moderate to low to very
low depending on the presence or lack of five factors described by
Higgins 2011 (see Table 2). We have presented our judgement of
the quality of the evidence with reasons in Summary of findings
for the main comparison.
Subgroup analysis and investigation of heterogeneity
If deemed appropriate, we intended to conduct subgroup analysis
to investigate if the treatment effects on the primary outcome
(functional recovery) varied in subpopulations. We planned the
following subgroup analyses.
• Time since stroke onset: to explore the effect of beginning
the intervention at varying times since stroke. The subgroups
were those where the intervention began within one month
poststroke, within one to three months poststroke, and between
three and six months poststroke. We used the mean time from
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stroke to intervention to identify participants that qualified for
inclusion.
• Treatments focused specifically on arm function versus
specifically on leg function.
• To determine if there was a difference between the side
effects in drugs that were globally acting or locally acting.
Sensitivity analysis
We planned a sensitivity analysis to assess the difference between
using RR and OR for the dichotomised outcomes.
R E S U L T S
Description of studies
See Characteristics of included studies, Characteristics of excluded
studies, Characteristics of studies awaiting classification.
Results of the search
Electronic and manual searches recovered 4064 records, of which
we identified 507 as being duplicates. Following review by two
review authors (CL and AK) of the remaining 3557 titles and
abstracts, we selected 59 for closer review, including eight where
there was no abstract available; see Figure 1. After reviewing the
full articles, we immediately excluded 20 articles, including all
eight without an abstract, as they did not meet the initial criteria.
At this point, we emailed the authors of 19 studies in which less
than 80% of included participants had a diagnosis of stroke or
which were cross-over studies to request further information. As
none of the authors responded, it was not possible to include these
studies. We finally accepted 20 full-text articles, of which 12 are
awaiting translation and so have been placed in Studies awaiting
classification. We therefore included eight articles. We did not
identify any ongoing studies.
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Figure 1. Study flow diagram.
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Included studies
We included seven randomised controlled trials involving 403 par-
ticipants (Bes 1988; Kirazli 1998; Kocabas 2010; Medici 1989;
Simpson 2009; Stamenova 2005; Yazdchi 2013); two articles re-
ported on the same study (Kirazli 1998).
Design
Only two studies were placebo controlled (Simpson 2009;
Stamenova 2005). Stamenova 2005 assessed a maximum dose of
900 mg tolperisone, while Simpson 2009 investigated both amax-
imum dose of 36 mg tizanidine and onabotulinumtoxinA against
placebo. As the stated objective of this review was to exclude bo-
tulinum toxin as a drug, we have not presented the 20 participants
in this trial who received onabotulinumtoxinA. We analysed these
two studies together as ’systemic drug versus placebo’.
The other five studies were all comparative studies investigating
one drug against another drug. Two of these studies compared a
systemic drug versus another systemic drug. Both of these studies
used tizanidine as the interventional drug but used different com-
parator drugs: Bes 1988 compared a maximum 12 mg tizanidine
with 15 mg diazepam, and Medici 1989 compared a maximum
20 mg tizanidine against a maximum dose of 50 mg baclofen.
One study investigated a systemic drug versus a locally acting drug
(Yazdchi 2013). This study assessed a maximum dose of 24 mg
tizanidine against a maximum dose of 1000 units abobotulinum-
toxinA.
The other two studies investigated a locally acting drug versus
another locally acting drug (Kirazli 1998; Kocabas 2010). Kirazli
1998 compared 3 ml of 5% phenol to 400 units onabotulinum-
toxinA, while Kocabas 2010 compared 5 ml of 5% phenol to 5
ml of 50% ethyl alcohol.
We have presented the results of these four distinct study groups
separately.
Sample sizes
The seven studies included 423 randomised participants, of which
403 participants relevant to this review were included (the remain-
ing 20 participants were randomised to botulinum toxin in the
Simpson 2009 study). Two of the studies had over 100 participants
each, meaning these two studies accounted for 56% of the entire
sample: Bes 1988 (105 participants) and Stamenova 2005 (120
participants). The two studies that assessed a systemic drug versus a
placebo had a combined total of 160 participants. The two studies
that compared a systemic drug versus another systemic drug had a
combined number of 135 participants (Bes 1988; Medici 1989).
The one study investigating a systemic drug versus a locally acting
drug had a sample size of 68 (Yazdchi 2013). The two studies that
compared a locally acting drug versus another locally acting drug
had notably small samples of just 10 participants in each group,
therefore the combined number of participants totaled 40 (Kirazli
1998; Kocabas 2010).
Interventions
Despite the variety of drugs that are currently used clinically to
treat spasticity, only three different drugs (tolperisone, tizanidine,
and phenol) were investigated against four different control drugs
(diazepam, baclofen, botulinum toxin, and alcohol). Of the three
trial drugs investigated, one was a locally acting drug (phenol),
and the other two were systemically acting drugs (tizanidine and
tolperisone).
Of the four control drugs used, twowere locally acting (botulinum
toxin or alcohol), and two were systemically acting (baclofen and
diazepam). None of the studies investigated exactly the same treat-
ments. Simpson 2009 andYazdchi 2013 both compared tizanidine
with botulinum toxin; however, as previously described, Simpson
2009 used a placebo arm as well. This review included only data
from the placebo and tizanidine arms of Simpson 2009; we will
include the botulinum toxin arm when we update the review to
include botulinum toxin.
Outcomes
In order to assess the primary research objective, we identified
outcome measures of general functional ability. Only two studies
included a general functional measure (Medici 1989; Stamenova
2005), while the other studies used measures of activity or im-
pairment. These two studies did not fall into the same category of
study design. Medici 1989 (’systemic drug versus systemic drug’
design) used a functional assessment called the Pedersen scale,
which is very rarely used, and dichotomised the results to im-
proved or deteriorated. They only reported results at 12 months,
despite assessments being carried out at monthly intervals up to six
months and then every other month to the 12-month assessment.
We did not attempt to contact these authors, as the publication
was more than 25 years old. These results are presented as odds ra-
tio. Stamenova 2005 (placebo design) assessed the Barthel Index;
however, they only presented the mean difference in Barthel. As
secondary anonymised data, such as standard deviation or 95%
confidence interval, were not available to review, this data could
not be pooled.
We intended to investigate activity measures of the arm separately
to the leg; however, given the lack of studies, this was not possible.
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Systemic drug versus a placebo
The two studies that investigated a systemically acting drug versus
a placebo both used functional measures, which were measured at
12 weeks. Simpson 2009 used the disability assessment scale, and
this data could be plotted. Stamenova 2005 used two measures of
functional ability; however, we were unable to analyse either. They
used the two-minute walk test, but only presented the results in
graph form, and a five-point ordinal scale of ability to perform
routine activities. This was deficient in that the table only gave
numbers in each group at pre- and end of study so that the number
who improved or deteriorated was not provided.
Systemic drug versus another systemic drug
The two studies that compared a systemic drug against another
systemic drug both measured a functional outcome. Medici 1989
used the Pedersen scale but also used a patient self assessment
of disability. The only stated result for the latter measure was an
improvement from baseline to 12 months (P < 0.001) in both
groups, but there was no significant difference between groups.
Bes 1988 measured walking distance over flat ground and rough
ground at eight weeks from baseline. The study authors did not
provide information of how the distance was achieved, as they did
not detail whether it was a timed walk or an endurance-limited
distance where the participant stopped when they could do no
more. As fewer participants were able to complete the walk on
rough ground, only the results of the flat ground were used. The
mean distance and standard deviation at baseline and eight weeks
were provided. In order to assess efficacy, we subtracted the mean
outcome measures at eight weeks from baseline. We calculated the
corresponding standard deviation (with an assumption for equal
variance) using methodology described in Daniel 1999.
Systemic drug versus a locally acting drug
In the one study that investigated a systemic drug against a lo-
cally acting drug, the baseline Action Research Arm Test (ARAT)
scores showed a significant difference between groups (P < 0.001)
(Yazdchi 2013). We used the same methodology as that of Daniel
1999 to estimate the corresponding standard deviation, having
subtracted the mean outcome measures at 12 weeks from baseline.
Locally acting drug versus another locally acting drug
Of the two studies that compared a locally acting drug against an-
other locally acting drug, Kocabas 2010 reported that visual anal-
ysis of gait showed that all participants in both groups improved
from baseline; however, the time at which this gait assessment was
completed was not described. This was the only outcome in this
study that related to function. Kirazli 1998 used a 25-foot timed
walk to measure function, which was completed at eight and 12
weeks postintervention. The report provided the mean difference
between baseline and 12 weeks with standard deviation.
As expected, the scales used to assess spasticity were diverse. Three
studies used the Ashworth scale (Kirazli 1998; Medici 1989;
Stamenova 2005), three used aModified Ashworth Scale (Kocabas
2010; Simpson 2009; Yazdchi 2013), and Bes 1988 used a novel
ordinal scale with similarities to the Ashworth Scale. As described
in the Methods, we planned to dichotomise the data, and we per-
formed this for five of the studies. We contacted the authors of the
two studies in which only the mean and standard deviation data
were provided, but they did not respond (Kirazli 1998; Yazdchi
2013).
Only Kirazli 1998 used an outcome measure that directly assessed
the abnormal muscle activity that is specific to spasticity. This
study presented a number of neurophysiological measures (see
Characteristics of included studies); however, only the H-reflex
and H(max):M(max) ratio were analysed.
Other measures of abnormal muscle activity included muscle
spasms and clonus as reported by Kocabas 2010 and Kirazli 1998.
These two studies also provided results of change in range ofmove-
ment at a joint; however, Kirazli 1998 only provided amean change
with no other data.
Adverse events were universally reported. They fell into three de-
fined categories (adverse events per participant, total adverse events
reported, and number of participants withdrawn due to side ef-
fects), with some studies reporting just one of these categories, and
others reporting two of the categories. We were able to pool all the
data from each category in the form of risk ratios.
Excluded studies
We excluded 19 studies (see Excluded studies). We excluded them
on the grounds that less than 80% of the participants had a diag-
nosis of stroke (11 studies: Burke 1975; Caruso 1977; Chipman
1974; Glass 1974; Harvey 1974; Knutsson 1982; Manca 2010;
Meythaler 2001a; Monster 1973; Monster 1974; Thompson
1966), or that a cross-over trial method had been used and the
pre cross-over data were not available (8 studies; Basmajian 1984;
Bovier 1985; Burt 1978; Civardi 1994; Katrak 1992; Maupas
2004; Medaer 1991; Meythaler 2001). We specified these two cri-
teria in the protocol and attempted to contact the lead author, cor-
responding author, or both to obtain the data needed to include
the study.
The eight cross-over studies had a mean (and median) date of
publication of 1991 (range 1978 to 2004). This is compared to
the included studies, where date of publication was mean 2002
and median 2005 (range 1988 to 2013).
Interventions of excluded studies
A total of 10 drugs were investigated in the 19 excluded trials,
reflecting the diversity of potential drugs available. Five of these
19 studies investigated dantrolene. None of the included studies
investigated this drug, despite its widespread clinical use.
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Studies awaiting classification
Twelve studies are awaiting classification (see Characteristics
of studies awaiting classification). All of these studies require
translation into English: four studies are Russian (Gekht 1998;
Kovalchuk 2008; Kovalchuk 2013; Stamenova 2006), three are
in Chinese (Cui 2009; Gan 2004; Yao 2004), and the rest are
in Dutch (Weynants 1990), Polish (Musiol 1977), Italian (Prati
1974), Spanish (Arbizu 1988), and Korean (Kim 2003).
These studies appear to have much larger sample sizes; for 10
studies where we could identify the numbers recruited, there were
a total of 964 participants.
Risk of bias in included studies
A summary of our judgement for each potential form of bias across
the included studies is provided in the ’Risk of bias’ graph in Figure
2. Our assessment of risk of bias for each individual study can be
found in the Characteristics of included studies table. The risk of
bias for each individual study is presented in a figurative form in
the ’Risk of bias’ summary in Figure 3. This helps identify that
only one study did not have a high risk of bias in any area.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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A poor response from study authors for further information neces-
sitated our assigning an unclear risk of bias as a large proportion
of our judgements. With the exception of Kocabas 2010, no other
study authors responded to our requests for further information.
Allocation
Random sequence generation and allocation concealment were
poorly described in all studies. As study authors did not respond to
our requests for further information, we had to assess all of these
studies as unclear risk of bias. Only Kocabas 2010 described the
sequence generation, which was by pitch and toss.
Blinding
Performance bias (blinding of participants and physician) tended
to be well reported, and we were able to make a clear decision
from the study reports in many cases; however, this was not the
case with detection bias (blinding of outcome assessors), which
was poorly reported. Due to this we classified four of the seven
studies as at unclear risk of bias (Bes 1988; Kocabas 2010; Medici
1989; Stamenova 2005).
Incomplete outcome data
There was a good level of reporting on participants lost to follow-
up in many studies, and in some cases no one was lost to follow-
up, allowing us to make a clear decision on whether there was
attrition bias.
Selective reporting
We found the highest risk of bias to be in the selective reporting
of data. Four of the seven studies did not adequately report all
the outcomemeasures described in themethodology.We reviewed
ClinicalTrials.gov andother potential resources to identifywhether
results had been registered in open access public forums, but this
was not the case.
Other potential sources of bias
We identified where commercial involvement appeared to have
occurred in Stamenova 2005, with the corresponding author an
employee of the drug company. Based on the available informa-
tion, it was not possible to identify any other sources of bias in the
studies.
Effects of interventions
See: Summary of findings for the main comparison Systemic
antispasticity drugs compared with placebo for spasticity after
stroke
See Summary of findings for the main comparison.
As described, there were four distinct groups of studies, and we
made comparisons between studies that for each of these four
categories.
Systemically acting drug versus a placebo
Functional ability during activities of daily living
Of the two studies that assessed a systemic drug against a placebo
(Simpson 2009; Stamenova 2005), only Simpson 2009 employed
any usable measure of function (Disability Assessment Scale). The
mean difference (MD) between the group receiving tizanidine (n
= 21) and the group receiving placebo (n = 19) was not significant
(MD -0.2, 95% confidence interval (CI) -0.9 to 0.5; Analysis 1.1).
Spasticity: indirect measure
Both of these studies had the measures of spasticity dichotomised;
however, this produced very heterogenous results (I2 = 85%).
While the results of Simpson 2009 were non-significant,
Stamenova 2005 showed a significant benefit for the treatment
group. When we pooled the data (160 participants), we did not
identify any significant effect (odds ratio (OR) 1.66, 95% CI 0.21
to 13.07; Analysis 1.2).
Adverse events
Stamenova 2005 reported two of the three defined categories of
adverse events (adverse events per participant and withdrawals due
to side effects), while Simpson 2009 reported all three categories,
including the total number of adverse events reported. The com-
bined data from both studies (160 participants) on adverse events
with a possible causal relationship to drug per participant demon-
strated a statistically significant (P = 0.01) risk to participants re-
ceiving the treatment drug compared with placebo (risk ratio (RR)
1.65, 95% CI 1.12 to 2.42). There was very little heterogeneity in
these results (I2 = 0%) (Analysis 1.3). Simpson 2009 also found
the total number of adverse events reported in each group to be
different. Ten adverse events were reported in the 19 participants
receiving placebo, whereas 24 adverse events were reported in 21
participants receiving treatment.
Despite the homogeneity of results for adverse events per partici-
pant, the two studies reported very heterogenous results on num-
bers withdrawndue to side effects (I2 = 62%).We therefore did not
identify any significant results (RR 1.16, 95% CI 0.04 to 34.40;
160 participants).
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Systemic drug versus another systemic drug
Functional ability during activities of daily living
The two studies that compared one systemic drug against another
systemic drug measured functional change in different ways (Bes
1988; Medici 1989).
Bes 1988 compared tizanidine against diazepam and assessed ben-
efit using a distance-walked test over flat ground (metres) as a
functional measure (79 participants, as not all participants could
walk). The study report stated that “only the patients on tizanidine
showed a statistically significant improvement in walking distance
on flat ground”; however, both groups achieved a statistically sig-
nificant improvement in distance walked. Indeed, there was a sta-
tistically significant difference (P = 0.01) between groups in favour
of diazepam when we calculated mean change from baseline to
eight weeks (MD -183.30, 95% CI -330.40 to -36.20; Analysis
2.1).
Medici 1989 compared tizanidine against baclofen and assessed
benefit using dichotomised data from the Pedersen scale, to mea-
sure function, and presented the arm and leg scores separately (30
participants). Both groups made equal improvements in the arm
and leg function, so there was no difference between groups for the
arm measure (OR 1.0, 95% CI 0.23 to 4.31) and the leg measure
(OR 1.0, 95% CI 0.17 to 5.98; Analysis 2.2).
Spasticity: indirect measure
Although the two studies used different scales tomeasure spasticity,
the response to treatmentwas dichotomised to identify responders.
However, we didnot pool the results, as the compareddrugs in each
studywere different.No significant differences betweendrugswere
identified in either study: Medici 1989 compared tizanidine with
baclofen (30 participants) and identified no significant difference
between groups (OR 2.36, 95% CI 0.36 to 15.45), and Bes 1988
compared tizanidine anddiazepam (78participants) and identified
no significant difference between groups (OR 0.90, 95% CI 0.37
to 2.20; Analysis 2.3).
Clonus and muscle spasms
Both studies also dichotomised signs of abnormal muscle activity
(e.g. clonus or muscle spasms) using customised scales. Not all
participants in the group had these signs, so the sample sizes in
the analyses were smaller than the study sample sizes. Both studies
presented the improvement in clonus. In Medici 1989 five out of
seven participants improved on tizanidine, compared with four
out of five on baclofen (0.63, 95% CI 0.04 to 9.65; 12 partici-
pants), whereas in Bes 1988 14 out of 29 participants in the ti-
zanidine group improved, compared with eight out of 20 on di-
azepam (1.40, 95%CI 0.44 to 4.44; 49 participants). Both studies
showed no significant differences between groups (Analysis 2.4).
In addition to clonus, Medici 1989 also assessed muscle spasms,
which were improved in five out of eight participants receiving
tizanidine and five out of six participants receiving baclofen (0.33,
95% CI 0.03 to 4.40; 14 participants; Analysis 2.5).
Adverse events
Bes 1988 reported two of the three defined categories adverse
events (total adverse events and withdrawals due to side effects),
while Medici 1989 reported all three categories, including the
number of adverse events per participant. In Medici 1989 there
was no significant difference between groups in the number of
adverse events per participant (RR 2.10, 95% CI 0.83 to 5.30; 29
participants). In both studies there were a greater number of total
adverse events in the tizanidine groups when compared with either
of the comparative drugs.While this difference was not significant
in Medici 1989 (RR 1.26, 95% CI 0.94 to 1.69; 29 participants),
there was a significant difference (P = 0.04) in favour of diazepam
in Bes 1988 (RR 1.22, 95% CI 1.01 to 1.48; 105 participants).
In both studiesmore participantswerewithdrawn from the control
group when compared with the tizanidine group; however, this
was not significant. Medici 1989 identified a non-significant RR
of 0.13 (95% CI 0.01 to 2.38), while Bes 1988 found an RR of
0.42 (95% CI 0.18 to 1.01) (Analysis 2.6).
Systemic drug versus a locally acting drug
Functional ability during activities of daily living
Yazdchi 2013 (68 participants) compared tizanidine against
abobotulinumtoxinA and used the Action Research Arm Test
(ARAT) as the outcome measure. We calculated the mean differ-
ence from baseline to week 12 and identified a significant differ-
ence (P = 0.02) in favour of botulinum toxin (MD 3.8, 95% CI
-6.93 to -0.65; Analysis 3.1).
Spasticity
This study did not present the results in a way that allowed any
measure of spasticity to be dichotomised. We contacted the cor-
responding author using the email address provided but did not
receive a response.
Adverse events
Adverse eventswere only presented as number of participantswith-
drawn due to side effects. This showed a significant risk ratio in
favour of botulinum toxin (RR 41.00, 95% CI 2.6 to 651.7; P =
0.009; 68 participants; Analysis 3.2).
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Locally acting drug against another locally acting drug
Functional ability during activities of daily living
Kocabas 2010 and Kirazli 1998 both compared phenol injections
against another locally acting drug (alcohol and onabotulinum-
toxinA, respectively). Kocabas 2010 only measured change at the
level of impairment, whereas Kirazli 1998 (20 participants) iden-
tified no significant mean difference between groups at 12 weeks
in a 25-foot timed walk test (MD 2.70, 95% CI -2.83 to 8.23;
Analysis 4.1).
Passive range of movement
Both studies provided information on range of movement at the
ankle; however, Kirazli 1998 only presented the mean change and
no other information with which to analyse the data. Kocabas
2010 presented this data, which once again showed no significant
difference between the two comparison drugs (P = 0.84; Analysis
4.2).
Spasticity: neurophysiological
Neither of the neurophysiological outcome measures used in
Kirazli 1998 (20 participants) demonstrated a significant dif-
ference between the groups. The mean difference between the
H(max):M(max) ratiowas -0.01 (95%CI -0.48 to 0.46; P = 0.97),
and the mean difference in H-reflex (amplitude) was 1.24 (95%
CI -1.44 to 3.92; P = 0.36; Analysis 4.3).
Spasticity: indirect measure
Kocabas 2010 (20 participants) provided dichotomised data for
the modified Ashworth scale only at the six-month assessment
but reported that all 20 participants had a decrease in the scale
immediately after the injection. This benefit was still present at
six-month follow-up in nine of the 10 participants treated with
alcohol and seven of the 10 in the phenol group, indicating no
significant difference between groups (OR 0.26, 95% CI 0.02 to
3.06; Analysis 4.4).
Clonus
In Kocabas 2010 the dichotomised results of clonus improvement
showed that all five participants treated with phenol and four of
seven participants treated with alcohol improved in clonus score.
There was no significant difference between the groups (OR 8.56,
95% CI 0.34 to 212.94; Analysis 4.5).
Adverse events
Kocabas 2010 and Kirazli 1998 both reported the total adverse
events occurring in the study. In both studies three of the 10
participants in the phenol groups reported adverse events while
none of the 10 participants in the control groups reported any
adverse events. There was no significant difference between groups
(RR 7.0, 95% CI 0.41 to 120.16; P = 0.18 ; I2 = 0%).
D I S C U S S I O N
Summary of main results
We identified seven randomised controlled trials with a combined
sample size of 403 participants that investigated a pharmacological
intervention for spasticity after stroke.
Just two of these studies were placebo-controlled trials, whereas in
the other five trials one drug was compared against another drug.
Only three different drugs (tolperisone, tizanidine, and phenol)
were investigated against four different control drugs (diazepam,
baclofen, botulinum toxin, and alcohol), and none of the studies
compared the same two drugs. We were able to pool data from the
two placebo trials with a combined sample size of 160 participants
(Simpson 2009; Stamenova 2005).
In addition to the two placebo studies, the studies could be divided
into three further categories. Two compared two systemic drugs
(Bes 1988; Medici 1989); one compared a systemic drug with
a local drug (Yazdchi 2013); and two compared two local drugs
(Kirazli 1998; Kocabas 2010).
Six studies used at least one functional outcomemeasure; however,
the results were not always reported in such a way as to allow
for data extraction and analyses (Bes 1988; Kirazli 1998; Medici
1989; Simpson 2009; Stamenova 2005; Yazdchi 2013). Kocabas
2010 measured all outcomes at an impairment level and did not
attempt to assess functional change.
Our primary objective was to determine if pharmacological inter-
ventions for spasticity are more effective than no intervention or
control at improving function following stroke. Clear evidence for
this was not available due to the lack of placebo-controlled trials
and the large variation in comparator trials. In the only placebo-
controlled study that employed usable outcome measures, results
were inconclusive (Simpson 2009). This trial was also the least
likely to be at risk of bias.
The results between the two placebo trials were divergent for treat-
ing spasticity, and meta-analysis of the data produced an I2 of
85%. Despite this heterogeneity in treating spasticity, there was
a clear increased risk of having an adverse event associated with
receiving tolperisone when compared with placebo.
Due to themethodology employed in comparing twodrugs against
each other, further results were limited. Treatment in current clini-
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cal practice varies among a number of drugs, so comparative meth-
ods are not useful in this area of investigation.
The methodology used to investigate whether the drug had in-
deed treated the specific impairment of spasticity varied. All of the
studies used a method based on the (modified) Ashworth Scale,
which has been shown to lack validity (Fleuren 2010; Pandyan
1999). Of the 79 participants who received a placebo drug, 39
(49.4%) of these improved according to the (modified) Ashworth
Scale. The one study using a direct measure of one aspect of spas-
ticity suggested that there was no difference between phenol and
botulinum toxin, both of which are locally acting. This suggests
a possibly large placebo effect or the effects of confounded mea-
surement (Fleuren 2010; Pandyan 1999).
In summary, this review has identified a lack of studies and sub-
sequent evidence relating to the use of pharmacological interven-
tions (with the exception of botulinum toxin) to treat spasticity.
The quality of the evidence is low to very low.
Overall completeness and applicability of
evidence
The completeness of evidence is limited by the methodology used
in many studies. Just two out of the seven studies used a placebo
control. We identified some studies using a cross-over placebo-
controlled methodology. We contacted the authors of these cross-
over studies, but none of them responded, which meant that we
could not include any of these studies in the analysis.
Themajority of outcomemeasures that measured function were at
the activity level rather than the participation level. The measures
employed differed for each study, and appropriate data were not
always reported to allow analysis.
In the two placebo-controlled trials, there was marked heterogene-
ity in the results for whether the intervention had treated spastic-
ity, which means that it is difficult to apply the evidence. The only
neurophysiological measure of spasticity did not show a significant
difference between phenol and botulinum toxin at 12 weeks.
Unfortunately, despite attempts to do so, it was not possible to
translate any of the full texts published in different languages into
English. Until this is achieved the evidence is not fully complete.
We expect to translate all of these studies into English by the time
that the review is updated.
Furthermore, due to initial editorial restrictions, we were not in a
position to include botulinum toxin as a pharmacological agent.
In the recent past the Cochrane Stroke Group Editorial Board
has approved that this review is updated with the inclusion of
botulinum neurotoxin type A. This process is ongoing, and the
results will be updated once we have collated the evidence and
carried out meta-analyses.
Quality of the evidence
The quality of the evidence varied. We judged six out of seven
studies to be at high risk of bias in at least one of the six method-
ological criteria assessed. Three of these studies had two compo-
nents that we judged to be at high risk of bias. The one study
we judged to have no evidence of high risk of bias did not have a
judgement made in three of the six components. We judged only
one study to be at low risk of bias in more than three components
(Simpson 2009). This studywas one of the two placebo-controlled
studies; however, we judged the quality of the other study using
this methodology to have two components at high risk of bias.
There is a risk of reduced internal validity associatedwith the use of
confounded measures in both the inclusion criteria for studies and
outcome measures. There was also inconsistency in reporting of
study results. In addition, the sample sizes in the included studies
were relatively low for drug trials; three studies had 30 or fewer
participants, and only two studies had a sample size of more than
100 participants.
Potential biases in the review process
Despite our extensive literature searching, selection bias is possi-
ble, and in particular publication bias. Furthermore, the inability
to gain access to the secondary anonymised data from the source
publications is also likely to have increased the chance of publi-
cation bias. Given the large numbers of participants in the stud-
ies awaiting classification and translation, it is possible that the
current conclusions may be biased towards studies that have been
published in English. We expect to translate all of these studies
into English by the time that the review is updated.
The inclusion of participants who had not had a stroke is a possi-
ble concern. However, the two studies that included participants
who had survived something other than a stroke only included
participants who had sustained a traumatic brain injury, and these
24 participants are unlikely to have had a major impact on any
conclusions made.
Agreements and disagreements with other
studies or reviews
Twoprevious systematic reviews have investigated this general area.
A review by Montane 2004 investigated oral antispastic drugs in
non-progressive neurological diseases, meaning that studies inves-
tigating traumatic brain injury, spinal cord injury, and cerebral
palsy were analysed as well as stroke. This review also included
the end data from cross-over trials, which we had stated in our
original protocol we would not include in our review. The authors
only identified 12 studies, two of which we have included in our
current review (Bes 1988; Medici 1989). They also included three
studies that we excluded from our review (Katrak 1992; Medaer
1991; Meythaler 2001a). We excluded Meythaler 2001a because
less than 80% of the participants had a diagnosis of stroke, and the
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other two studies because they were studies with a cross-over de-
sign.Despite themethodological differences between theMontane
2004 review and our review, the conclusions were similar.
A more recent review by Olvey 2010 investigated only people
with a history of stroke but also specifically arm spasticity. This
review used just nine search terms and included only drugs avail-
able commercially in the United States. The methodology also in-
cluded studies that were not randomised. Importantly, this review
included studies which investigated botulinum toxin. Of the 54
studies that met the inclusion criteria, 51 of them involved bo-
tulinum toxin. The other three studies were uncontrolled trials
of tizanidine and intrathecal baclofen, and one cross-over trial in-
vestigating intrathecal baclofen that we excluded from our review
(Meythaler 2001). The one trial that was included in both the
review by Olvey 2010 and our review was Simpson 2009. Due to
methodological differences, it is not appropriate to compare our
review with Olvey 2010.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is currently insufficient high-quality evidence to make gen-
eralisable conclusions about the effect of pharmacological inter-
ventions on spasticity in people with stroke. Furthermore, we
found some very low-quality evidence that suggests there is an in-
creased risk of adverse effects in people who take antispasmodics
when compared with placebo. We therefore cannot recommend
pharmacological interventions as first-line treatment for people
with spasticity after stroke. If a clinical decision is made to admin-
ister any of these interventions, particular care should be taken to
monitor for adverse effects.
Implications for research
This review has highlighted the lack of high-quality research into
the use of pharmacological interventions to treat spasticity follow-
ing stroke (with the exception of botulinum toxin).
Future research should implement high-quality randomised trial
methodology, which will help in reducing potential bias in the
results. Future research should also employ placebo controls to
assess the efficacy of an intervention. The use of comparative drug
trials has meant we have been unable to meta-analyse the stud-
ies, with the exception of the two studies that did use a placebo
control. If a clear gold standard first-line drug is identified, then
comparative drug trials may be worthwhile in identifying novel
drugs; however, this does not appear to currently be the case. If
a comparison study is employed, a clear rationale for use of the
comparative drug should be given.
Future investigations should also use an assessment tool that is
capable of identifying whether the drug being investigated has ac-
tually stopped the abnormal muscle activity related to spasticity
from occurring. Current approaches that use indirect measures of
stiffness are confounded by coexisting contractures. Only when
it is evident that spasticity has been treated should methods that
investigate functional changes also be measured. Even if the cur-
rent review had identified a number of high-quality placebo-con-
trolled trials with large sample sizes, it might not have been possi-
ble to conclude that antispasmodics were effective. If the primary
impairment being measured cannot be shown to have been im-
proved, then any functional recovery seen between groups cannot
be causatively associated with the drug.
Once these questions have been answered it will be important for
future research to then focus on the optimal time at which to ini-
tiate treatments and the ideal dose associated with each treatment.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bes 1988
Methods Randomised, double-blind, comparative study
Objective: to compare the efficacy and tolerability of tizanidine with that of diazepam
Participants France
105 recruited adults (28 females, 77 males), of which 89 had a diagnosis of stroke, were
randomly divided in 2 groups (the other 16 had TBI)
Tizanidine group had a mean age of 51.4 (SD 2.2)
Diazepam group had a mean age of 51.8 (SD 2.4)
Interventions A starting dose of one 2 mg tizanidine (Sirdalud) capsule was titrated up by 2 mg every
2 days to a maximum of 24 mg/day
A starting dose of one 2.5 mg diazepam capsule was titrated up by 2.5 mg every 2 days
to a maximum of 30 mg/day
Outcomes Dichotomised data for clonus, spasticity, muscle strength. The stretch reflex was analysed
during extension at a constant rate (defined as the rate of fall of the limb due to gravity)
of four groups of muscles - forearm flexors, quadriceps, knee flexors and triceps surae.
The duration of any resulting contracture and the angle at which it appeared were noted
Walking distance was also measured. Measures at 2 and 8 weeks
Spasticity and inclusion No definition of spasticity provided. but inclusion criteria specified that spasticity “was
severe enough to interfere with daily activities”. Spasticity was measured using a 1 to 5
rating scale
Notes Not able to make contact with authors (26 years since study)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk There is no description of how sequence
generation was achieved
Allocation concealment (selection bias) Unclear risk There is no description of how sequence
generation was achieved
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Appears that capsules for both drugs were
the same so that investigator and partici-
pant were blinded to treatment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It is unclear whether the evaluating physi-
cian was blinded at all outcomes
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Bes 1988 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk 28% of 1 group was lost to follow-up at 8-
week assessment
Selective reporting (reporting bias) High risk All assessment measures described in the
methodology were subsequently reported.
The authors have deemed reporting bias to
be high risk because a statistically signifi-
cant improvement in walking distance on
flat ground was reported in the tizanidine
group only.On calculation, both the tizani-
dine and diazepam group had made statis-
tically significant improvements
Kirazli 1998
Methods Randomised, double-blind comparison study
Objective: “Does botulinus toxin Type A and phenol relieve the signs and symptoms
of ankle plantar flexor and foot invertor spasticity after stroke and do either of these
methods offer any advantages and disadvantages over the other?”
Participants Turkey
20 adults (6 female, 14 male)
Mean age of 50.3 years (SD 17.8) with a diagnosis of stroke (10 thrombotic, 6 embolic,
4 haemorrhagic) at least 6 months ago were randomly divided into 2 groups
Interventions 3 ml of 5% phenol injected into tibial nerve approximately 7 cm above popliteal crease
and localised by percutaneous stimulation
Total of 400 units onabotulinumtoxinA (50 units/1 ml injected with electrical stimula-
tion guidance)
100 units into soleus, 100 units into tibialis posterior, 100 units into lateral head of
gastrocnemius, and 100 units into medial head of gastrocnemius
Outcomes Electrophysiological measures (Achilles TendonReflex (ATR) (milliVolts (mV)),M-wave
(mV), H-reflex (mV), H:M ratio, ATR:H ratio)
Ashworth Scale: mean and standard deviations at ankle dorsiflexion and eversion
Timed walk (25 feet) (seconds)
Clonus duration (seconds)
Global assessment of spasticity: participant subjective report
Dichotomous improvement in active and passive range of movement at ankle and in
wearing of ankle brace
Adverse events
Spasticity and inclusion Spasticity was defined as “typically includes hyperactive phasic stretch reflexes with ve-
locity dependent hypertonus”
To be included spasticity had to be “severe” (Ashworth Scale = 3 or 4) and stable for at
least 2 months
(0 = no increase in muscle tone, 4 = limb rigid in flexion or extension)
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Kirazli 1998 (Continued)
Notes We contacted the 2 lead authors by email but received no response
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No explanation provided in either report
Allocation concealment (selection bias) Unclear risk No explanation provided in either report
Blinding of participants and personnel
(performance bias)
All outcomes
High risk 2 different procedures carried out by the
injector means they were not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Clear description of blinding by assessor
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants were accounted for
Selective reporting (reporting bias) Low risk All assessment measures described in the
methodology of both reports were subse-
quently reported
Kocabas 2010
Methods Randomised, double-blind comparison study
Objective: “To determine whether the injection of alcohol or phenol into the tibialis
posterior nerve relieves symptoms and signs of ankle plantar flexor spasticity.”
Participants Turkey
20 adults (6 female, 14 male) with a diagnosis of stroke (14 infarct and 6 haemorrhagic)
were randomly divided into 2 groups
Alcohol group had mean age of 55.6 (SD 13.7) and 21.4 (SD 16.0) months poststroke
Phenol group had mean age of 51.9 (SD 27.7) and 22.8 (SD 27.8) months poststroke
Interventions 5 ml of 5% phenol - motor branches of tibial nerve
5 ml of 50% ethyl alcohol - motor branches of tibial nerve
Outcomes Modified Ashworth Scale
Clonus Score: 0 (absent), 1 (unsustained), 2 (sustained), 3 (spontaneous/light-touch
provoked)
Dichotomous changes in clonus and strength
Passive range of movement in degrees
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Kocabas 2010 (Continued)
Spasticity and inclusion Spasticity was not defined. To be included the person had to have “severe ankle plantar
flexor spasticity” (Modified Ashworth Scale ≥ 2) (0 = no increase in muscle tone, 4 =
limb rigid in flexion or extension)
Notes Grateful thanks to Dr Hilal Kocabas who responded to our request for further details
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Pitch and toss method used for randomisa-
tion
Allocation concealment (selection bias) Unclear risk Givenmethodof randomisation, allocation
concealment was potentially at risk; as it
was not possible to be sure, we judged it as
unclear risk
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk It is unclear whether the injecting physi-
cian was blinded to which drug the syringe
contained
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessor is not explic-
itly stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants were accounted for
Selective reporting (reporting bias) High risk Information on strength was not reported
adequately to identify changes.While com-
plications occurred in gait, it was unclear
in which groups this occurred
Medici 1989
Methods Randomised, double-blind, comparative study
Objective: To compare the long-term efficacy and tolerability of tizanidine with that of
baclofen in the treatment of spasticity due to cerebrovascular lesions
Participants Uruguay
30 adults (6 female, 24 male) with a diagnosis of stroke (a mean 3.5 (0.1 to 14) years
before) were randomly divided into 2 groups
Tizanidine (Sirdalud) group had mean age 50 years (22 to 73)
Baclofen group had mean age of 49 years (24 to 68)
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Medici 1989 (Continued)
Interventions A starting dose of 2 x 4 mg tizanidine capsules was titrated up by 4 mg every 3 days to
a maximum of 20 mg/day
A starting dose of 2 x 10 mg baclofen capsules was titrated up by 10 mg every 3 days to
a maximum of 50 mg/day
Outcomes Dichotomised results of muscle tone (measured using the Ashworth Scale). Ordinal
scales for muscle spasms, clonus, and strength were studied. Functional assessment used
the Pedersen scale of the arm or leg. A participant self assessment of disability ordinal 4-
point scale and participant and assessor assessment of antispastic effect using an ordinal
4-point scale
Endpoint analysis not explicitly stated but appears to be 12 months
Spasticity and inclusion Spasticity was not defined, and the level of spasticity required to participate in the trial
was not reported
Notes Not able to make contact with authors (25 years since study)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk There is no description of how sequence
generation was achieved
Allocation concealment (selection bias) Unclear risk There is no description of how allocation
concealment was achieved
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk It appears that capsules for both drugs were
the same so that investigator and partici-
pant were blinded to treatment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Details on blinding of the assessor are not
described
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT and per-protocol data provided
Selective reporting (reporting bias) Low risk All assessment measures described in the
methodology were subsequently reported
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Simpson 2009
Methods Randomised, double-blind, 3-arm, placebo-controlled study
Due to mandate of review, only the tizanidine and placebo groups are reported - the
botulinum toxin arm is not reported
Participants USA
40 adults (19 female, 21 male) of which 32 had a diagnosis of stroke were randomly
divided into 2 groups (the other 8 had TBI)
Tizanidine group had mean age of 51.9 years (SD 17.3)
Placebo group had mean age of 51.3 years (SD 14.7)
Interventions Tizanidine starting dose of 2 mg/day titrated up by 4mg every 3 to 4 days to a maximum
of 36 mg/day; also received at least 2 placebo injections to forearm muscles
Placebo group provided with placebo oral medication; also received at least 2 placebo
injections to forearm muscles
Outcomes Modified Ashworth Scale at the wrist and finger flexors
Modified Ashworth dichotomised
Disability Assessment Scale: 1 domain was identified by the participant and assessor as
the primary therapeutic target
Modified Frenchay Scale, 10-Metre Walk Test, contralateral grip strength, and Finger
Tap Test
Other measures included Epworth Sleepiness Scale, Geriatric Depression Scale, and
Letter-Number Sequencing
Spasticity and inclusion Spasticity was not defined. Evidence of spasticity was a score of ≥ 3 on the Modified
Ashworth Scale (0 normal tone and 5 rigid flexion)
Notes We contacted 2 of the authors by email but received no response
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk There is no description of how sequence
generation was achieved
Allocation concealment (selection bias) Low risk The review authors assume that allocation
concealment was maintained
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Both participants and injectors were
blinded to treatment. Clear explanation
provided
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The outcome assessor was blinded to the
treatment
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Simpson 2009 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition was documented for all groups
and explanations provided. At primary
endpoint 93% of participants were as-
sessed. We noted that there was a high at-
trition rate between week 6 and week 22
Selective reporting (reporting bias) High risk Planned data for report were presented at
primary endpoint in the report; however,
there has been no follow-up report ofMod-
ified Frenchay Scale and 10-Metre Walk
Test results from the study
Stamenova 2005
Methods Randomised, double-blind, placebo-controlled study
Objective: To study the efficacy and safety of tolperisone in the treatment of stroke-
related spasticity
Participants Bulgaria and Germany
120 adults (43 female, 77 male) with a diagnosis of stroke (a mean 3.3 (SD 4.4) years
before) were randomly divided into 2 groups
Tolperisone group had mean age of 64.2 years (SD 10.9)
Placebo group had mean age of 62.3 years (SD 10.2)
Interventions The starting dose was 2 x 50 mg tablets of tolperisone hydrochloride (Mydocalm) 3
times a day
The dose was titrated up to 3, 4, or 6 tablets 3 times a day at 5-day intervals so that a
maximum dose of 900 mg tolperisone was achieved
Placebo tablets were given in the same dose and titrated up as per the drug protocol
Outcomes The mean change to baseline in the Barthel Index (0 to 100) and Modified Ashworth
Scale was reported
The Modified Ashworth was dichotomised, and overall efficacy was dichotomised in
graphical form
2-Minute Walk Test was carried out
Elbow stiffness was measured using a spring balance
Capacity to perform routine activities on a 5-point ordinal scale
Overall efficacy was measured by participant and assessor using a 4-point ordinal scale
Spasticity and inclusion Spasticity was defined as a velocity-dependent increase in the resistance of muscles to
passive stretch associated with exaggerated tendon jerks
To be included the person had to have an Ashworth Scale ≥ 2 in at least 1 joint
Notes We contacted the corresponding author by email but received no response
Risk of bias
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Stamenova 2005 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk There is no description of how sequence
generation was achieved
Allocation concealment (selection bias) Unclear risk There is no description of how allocation
concealment was achieved
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participant blinding appears to have been
wellmaintained. Tablets reported as having
same appearance
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It is unclear whether the evaluating physi-
cian was blinded at all outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT and per-protocol data provided
Selective reporting (reporting bias) High risk The results of the force required to extend
the elbow are not reported
Other bias High risk This study appears to have had pharmaceu-
tical industry involvement; however, there
is no declaration of interests. The corre-
sponding author was an employee of the
company that produced the drug under in-
vestigation
Yazdchi 2013
Methods Randomised, double-blind, comparative study
Objective: “To evaluate the efficacy of focal intramuscular injection of botulinum toxin
type A (BoNT) in comparison with oral tizanidine in treatment of post-stroke upper
extremity’s spasticity”
Participants Iran
68 adults (29 females, 39 males)
Mean age of 66.1 years (35 to 70) with a diagnosis of stroke at least 3 months ago were
randomly divided into 2 groups
Interventions A starting dose of one 2 mg tizanidine (Sirdalud) (Novartis) capsule was titrated up by
2 mg every week to a maximum of 24 mg/day at week 12
Repeated injections at baseline and 12 weeks; maximum dose of 1000 units of abobo-
tulinumtoxinA into arm muscles deemed appropriate by clinician
Outcomes Elbow and wrist Modified Ashworth scale and Action Research Arm Test
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Yazdchi 2013 (Continued)
Spasticity and inclusion “Spasticity is an increased resistance impassive movement at a joint that depends upon
velocity of an action.” Adults with a minimum score of 2 on the Modified Ashworth
scale were included
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk There is no description of how sequence
generation was achieved
Allocation concealment (selection bias) Unclear risk There is no description of how sequence
generation was achieved
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were either injected or not, in-
dicating that they were not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessor was blinded to treatment at all
points
Incomplete outcome data (attrition bias)
All outcomes
High risk 20 participants in 1 group withdrew due
to side effects, whereas no participants in
the other group withdrew. Other eligible
participants replaced those who withdrew
Selective reporting (reporting bias) Unclear risk All assessment measures described in the
methodology were subsequently reported
H-reflex: Hoffmann reflex
ITT: intention-to-treat
SD: standard deviation
TBI: traumatic brain injury
Characteristics of excluded studies [ordered by study ID]
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Study Reason for exclusion
Basmajian 1984 Cross-over study 1984; unable to contact
Bovier 1985 Cross-over study 1985; unable to contact
Burke 1975 < 80% diagnosed with stroke (21% stroke)
Burt 1978 Cross-over study 1978; unable to contact
Caruso 1977 < 80% diagnosed with stroke (61.5% stroke)
Chipman 1974 < 80% diagnosed with stroke (23% stroke)
Civardi 1994 Cross-over study 1994; unable to contact
Glass 1974 Unclear diagnosis of participants who were in RCT
Harvey 1974 < 80% diagnosed with stroke (21% stroke)
Katrak 1992 Cross-over study; emailed first author but received no response
Knutsson 1982 < 80% diagnosed with stroke (6% stroke)
Manca 2010 < 80% diagnosed with stroke (77% stroke)
Emailed first author but received no response
Maupas 2004 Cross-over study; emailed first author but received no response
Medaer 1991 Cross-over study 1991; unable to contact
Meythaler 2001 Cross-over study; emailed first author but received no response
Meythaler 2001a < 80% diagnosed with stroke (53% stroke)
Emailed first author but received no response
Monster 1973 < 80% diagnosed with stroke (34% stroke)
Monster 1974 < 80% diagnosed with stroke (35% stroke)
Thompson 1966 < 80% diagnosed with stroke (39% stroke)
RCT: randomised controlled trial
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Characteristics of studies awaiting assessment [ordered by study ID]
Arbizu 1988
Methods Randomised, double-blind, comparative study
Participants 27 adults (8 females, 19 males)
Interventions Tizanidine (Sirdalud) and baclofen
Outcomes Ashworth Scale
Language Spanish
Notes Information from abstract
Cui 2009
Methods Randomised, 4-arm, placebo-controlled study
Participants 103 adults diagnosed with stroke
Interventions Tizanidine (n = 30), baclofen (n = 25), eperisone (n = 22), and control (n = 26)
Outcomes Modified Ashworth Scale, Fugl-Meyer Assessment, and Modified Barthel Index 4 weeks prior to trial and 12 weeks
after the medication
Language Chinese
Notes Information from abstract
Gan 2004
Methods RCT
Participants 60 adults diagnosed with stroke
Interventions 50 mg eperisone 3 times/day for 1 month; control group unclear
Outcomes Ashworth Scale, Brunnstrom at weeks 2 and 4
Language Chinese
Notes Information from abstract
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Gekht 1998
Methods Unclear
Participants 94 adults diagnosed with stroke (aged 42 to 70 years)
Interventions Tizanidine (Sirdalud)
Outcomes Not reported
Language Russian
Notes Information from abstract
Kim 2003
Methods RCT. Objective: “To evaluate quantitatively the effect of tizanidine on spasticity reduction and to evaluate the effective
and tolerable dosage of it in stroke patients”
Participants 24 adults diagnosed with stroke divided into 2 groups
Interventions Tizanidine and control group
Outcomes Biomechanical-neurophysiological assessment
Language Korean
Notes Information from abstract
Kovalchuk 2008
Methods Unclear
Participants 360 adults diagnosed with stroke
Interventions Tolperisone, tizanidine, and others
Outcomes Ashworth, Barthel, Lindmark, Scandinavian, and Merton & Sutton scales, 2-Minute Walk Test
Language Russian
Notes Information from abstract
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Kovalchuk 2013
Methods Not clear what methodology was used
Participants 1700 adults diagnosed with stroke divided into 2 groups (850 in each group)
Interventions Tolperisone and control group
Outcomes Ashworth, Barthel, Lindmark, Scandinavian, and Merton & Sutton scales
Language Russian
Notes Information from abstract
Musiol 1977
Methods Unclear
Participants 12 adults
Interventions Baclofen (Lioresal)
Outcomes Novel grade system (1 = normal tonus; 5 = high-grade hypertonus)
Language Polish
Notes Abstract in Polish
Prati 1974
Methods Unclear
Participants -
Interventions Baclofen
Outcomes -
Language Italian
Notes Abstract in Italian
Stamenova 2006
Methods Randomised, double-blind, placebo-controlled trial
Participants 120 adults diagnosed with stroke
Interventions Tolperisone
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Stamenova 2006 (Continued)
Outcomes -
Language Russian
Notes Appears to be the same study as Stamenova 2005
Weynants 1990
Methods Unclear
Participants 20 adults (17 diagnosed with stroke), mean age 50 years (range 15 to 69)
Interventions Tizanidine
Outcomes -
Language Dutch
Notes Abstract in Dutch
Yao 2004
Methods RCT
Participants 144 adults with stroke
Interventions Baclofen (n = 84), control (n = 60)
Outcomes Ashworth, Fugl-Meyer Assessment, and Modified Barthel Index
Language Chinese
Notes Information from abstract
RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Systemic drug versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Function 1 40 Mean Difference (IV, Random, 95% CI) -0.20 [-0.90, 0.50]
1.1 Disability Assessment
Scale
1 40 Mean Difference (IV, Random, 95% CI) -0.20 [-0.90, 0.50]
2 Spasticity - indirect measure 2 160 Odds Ratio (M-H, Random, 95% CI) 1.66 [0.21, 13.07]
3 Adverse events 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Adverse events per
participant
2 160 Risk Ratio (M-H, Random, 95% CI) 1.65 [1.12, 2.42]
3.2 Participants withdrawn
due to side effects
2 160 Risk Ratio (M-H, Random, 95% CI) 1.16 [0.04, 34.40]
Comparison 2. Systemic drug versus another systemic drug
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Function 1 Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 Gait 1 79 Mean Difference (IV, Random, 95% CI) -183.3 [-330.40, -
36.20]
2 Function dichotomous 1 Odds Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Pedersen Scale - upper
limb
1 30 Odds Ratio (M-H, Random, 95% CI) 1.0 [0.23, 4.31]
2.2 Pedersen Scale - lower
limb
1 30 Odds Ratio (M-H, Random, 95% CI) 1.0 [0.17, 5.98]
3 Spasticity - indirect measure 2 Odds Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Tizanidine versus baclofen 1 30 Odds Ratio (M-H, Random, 95% CI) 2.36 [0.36, 15.45]
3.2 Tizanidine versus
diazepam
1 78 Odds Ratio (M-H, Random, 95% CI) 0.90 [0.37, 2.20]
4 Clonus 2 Odds Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Tizanidine versus baclofen 1 12 Odds Ratio (M-H, Random, 95% CI) 0.63 [0.04, 9.65]
4.2 Tizanidine versus
diazepam
1 49 Odds Ratio (M-H, Random, 95% CI) 1.4 [0.44, 4.44]
5 Muscle spasms 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Tizanidine versus baclofen 1 14 Odds Ratio (M-H, Fixed, 95% CI) 0.33 [0.03, 4.40]
6 Adverse events 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 Per participant - tizanidine
versus baclofen
1 29 Risk Ratio (M-H, Random, 95% CI) 2.1 [0.83, 5.30]
6.2 Total- tizanidine versus
baclofen
1 29 Risk Ratio (M-H, Random, 95% CI) 1.26 [0.94, 1.69]
6.3 Total - tizanidine versus
diazepam
1 105 Risk Ratio (M-H, Random, 95% CI) 1.22 [1.01, 1.48]
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6.4 Withdrew - tizanidine
versus baclofen
1 29 Risk Ratio (M-H, Random, 95% CI) 0.13 [0.01, 2.38]
6.5 Withdrew - tizanidine
versus diazepam
1 105 Risk Ratio (M-H, Random, 95% CI) 0.42 [0.18, 1.01]
Comparison 3. Systemically acting drug versus a locally acting drug
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Function 1 Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 Action Research Arm Test 1 68 Mean Difference (IV, Random, 95% CI) -3.79 [-6.93, -0.65]
2 Adverse events 1 68 Risk Ratio (M-H, Random, 95% CI) 41.00 [2.58, 651.70]
Comparison 4. Locally acting drug versus another locally acting drug
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Function 1 Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 Gait (25 feet timed walk) 1 20 Mean Difference (IV, Random, 95% CI) 2.70 [-2.83, 8.23]
2 Passive range of movement 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 Phenol versus alcohol 1 20 Mean Difference (IV, Fixed, 95% CI) 1.0 [-7.00, 11.00]
3 Spasticity - neurophysiological 1 Mean Difference (IV, Random, 95% CI) Subtotals only
3.1 H:M Ratio 1 20 Mean Difference (IV, Random, 95% CI) -0.01 [-0.48, 0.46]
3.2 H-reflex 1 20 Mean Difference (IV, Random, 95% CI) 1.24 [-1.44, 3.92]
4 Spasticity - indirect measure 1 Odds Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Phenol versus alcohol 1 20 Odds Ratio (M-H, Random, 95% CI) 0.26 [0.02, 3.06]
5 Clonus 1 Odds Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Phenol versus alcohol 1 12 Odds Ratio (M-H, Random, 95% CI) 8.56 [0.34, 212.94]
6 Adverse events 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 Total - phenol versus
alcohol
1 20 Risk Ratio (M-H, Random, 95% CI) 7.0 [0.41, 120.16]
6.2 Total - phenol versus
botulinum toxin
1 20 Risk Ratio (M-H, Random, 95% CI) 7.0 [0.41, 120.16]
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A D D I T I O N A L T A B L E S
Table 1. Pharmacological agents for treating spasticity after stroke
Generic name Method of administration Method of action
Baclofen Oral, intrathecal pump Baclofen is a centrally acting gamma-aminobutyric acid (GABA) analogue that limits
the release of excitatory neurotransmitters in the spinal cord (Mukherjee 2010). It
binds toGABA receptors at the presynaptic terminal and inhibits the influxof calcium
into the presynaptic terminal, decreasing both mono- and polysynaptic reflexes (
Davidoff 1985; Krach 2001). It also binds on the postsynaptic terminal of the 1a
sensory afferent (Howe 1987)
Tizanidine Oral An imidazole derivative with agonist action on alpha-2-adrenergic receptors in the
central nervous system (Mukherjee 2010). It has an effect both pre- and postsy-
naptically and decreases the level of excitatory neurotransmitter between the spinal
interneurons to the alpha motor neurons through presynaptic inhibition (Gallichio
2004). It may also inhibit abnormal activity by acting on locus coeruleus and in-
hibiting activity in the coerulospinal pathway (Palmeri 1990)
Dantrolene Oral This drug acts at the muscle level rather than the neural level and affects both intra-
and extrafusal muscles (Gallichio 2004). It interferes with the release of calcium
from the sarcoplasmic reticulum of the muscle (Mukherjee 2010). This decrease in
available calcium reduces the force produced during a contraction (Gallichio 2004)
Tolperisone Oral Centrally acting muscle relaxant that acts at the spinal cord level. Primarily acts
presynaptically to inhibit both calcium and sodium channels. Decreases reflex activity
by inhibiting release from the primary afferent (Vora 2010)
Alcohol Injection The effect of alcohol varies depending on the concentration. At concentrations below
35%, it acts as a local anaesthetic. In concentrations between 35% to 50% small-
fibre demyelination was observed, but in concentrations above this level, Wallerian
degeneration and fibrosis are observed (Kocabas 2010)
Phenol Injection, intrathecal The effect of phenol also varies depending on concentrations used. It can be injected
either into the muscle or directly into the nerve. At concentrations greater than
3%, protein denaturation and axonal degeneration destroy the neurons. 5% phenol
injection to the motor points of the muscle lead to demyelination of the neuron
(Kocabas 2010).
Table 2. Factors that may decrease the quality of the evidence
1. Limitations in the design and implementation of available studies suggesting high likelihood of bias
2. Indirectness of evidence (indirect population, intervention, control, outcomes)
3. Unexplained heterogeneity or inconsistency of results (including problems with subgroup analyses)
4. Imprecision of results (wide confidence intervals)
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Table 2. Factors that may decrease the quality of the evidence (Continued)
5. High probability of publication bias
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Outcome measures
We expected to identify studies that investigated varying doses of the same drug. In the protocol we explained how we would deal with
such studies. However, we did not identify any such trials, so we have not included this section in the methodology.
We provided examples in our protocol of functional activity scales of the upper limb and lower limb that might be included, such
as Action Research Arm Test (ARAT), appropriate subsections of motor assessment scale or Wolf Motor Function Test or Functional
Ambulatory Classification or Functional Gait Assessment. It was not possible to analyse the data due to a lack of such objective measures
in the included studies.
This was also the case for timed measures of specific activities. Again, such temporal measures can be divided into upper limb and lower
limb measures. Upper limb temporal measures might have included the 9-Hole Peg Test or Jebsen Hand Function Test. Lower limb
temporal measures might have included the Timed 10-Metre Walk Test or Get-up and Go Test.
Risk of bias
The protocol for this review explained that wewould investigate risk of bias in two specific domains first: ’selection bias’ and ’performance
and detection bias’. Only in studies deemed to have a low risk of bias in these two domains would we carry out further analysis. We
suggested in the protocol that we would exclude studies deemed to have a high risk of bias in these two domains. We investigated all
included studies for risk of bias in all the domains at the same time point because this was easier for the review authors, but also because
we were not going to exclude papers deemed at high risk in these two domains.
Reporting bias
We planned to use a funnel plot of the standard error of the intervention effect to identify asymmetry. This was not completed due to
a lack of studies.
Results
The results were presented differently in different studies. Some studies only presented the response at a single joint, other studies
presented the results of the joints where most effect was observed, and other studies presented the results of a number of joints. In
order to present the results uniformly, we have provided the most conservative results. An example of this are the results from Simpson
2009. The results at the wrist showed 12 people in the placebo group improved versus five in the treatment group, and at the fingers
seven in the placebo group and seven in the treatment group improved. In this case we used the five from the wrist to represent the
treatment group and the seven from the finger to represent the placebo group. In Bes 1988, arm and leg joints were assessed, but not
all participants had spasticity at every joint. We analysed the results of the wrist flexors, as the most participants had spasticity at this
joint.
Subgroup analysis and investigation of heterogeneity
We could not conduct any of the intended subgroup analyses because of the lack of data.
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N O T E S
Simpson 2009 was a three-arm trial comparing tizanidine versus botulinum toxin versus placebo.On initial data extractionwe considered
that only the comparison of tizanidine versus placebowas relevant to this review, andwe have included only data for these arms.However,
we identified and have included other trials that had botulinum toxin as the comparator (Kirazli 1998 compared phenol to botulinum
toxin, and Yazdchi 2013 compared tizanidine to botulinum toxin). On reflection, our decision to exclude the botulinum toxin arm
of the Simpson 2009 trial was incorrect, and the comparison of tizanidine versus botulinum toxin should have been included in the
comparison ’Systemic drug versus a locally acting drug’. This inconsistency was noted at the final editorial stages prior to publication
of this review, and we have made no correction to this version of the review. We will broaden future updates of this review to include all
pharmacological interventions for spasticity (i.e. we will include botulinum toxin as an active intervention). We will therefore include
the botulinum toxin arm of the Simpson 2009 trial in future updates.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Baclofen [therapeutic use]; Botulinum Toxins, Type A [therapeutic use]; Clonidine [analogs & derivatives; therapeutic use]; Diazepam
[therapeutic use]; Muscle Relaxants, Central [therapeutic use]; Muscle Spasticity [∗drug therapy]; Randomized Controlled Trials as
Topic; Stroke [∗complications]; Tolperisone [therapeutic use]
MeSH check words
Humans
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